Mirvetuximab Soravtansine Market Size, Forecast, and Drug Insight - 2032

"Mirvetuximab Soravtansine Market Size, Forecast, and Drug Insight - 2032" report provides comprehensive insights about mirvetuximab soravtansine for ovarian cancer in the seven major markets. A detailed picture of the mirvetuximab soravtansine for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mirvetuximab soravtansine for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mirvetuximab soravtansine market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRa)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family, is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug-resistant tumor cells. It is being studied in later line platinum-sensitive ovarian cancer and in combination in both platinum-resistant and platinum-sensitive diseases.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the mirvetuximab soravtansine description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on mirvetuximab soravtansine regulatory milestones and other development activities have been provided in this report.
• The report also highlights the mirvetuximab soravtansine research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around mirvetuximab soravtansine.
• The report contains forecasted sales of mirvetuximab soravtansine for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for mirvetuximab soravtansine in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Mirvetuximab Soravtansine Analytical Perspective by DelveInsight

• In-depth Mirvetuximab Soravtansine Market Assessment

This report provides a detailed market assessment of mirvetuximab soravtansine for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Mirvetuximab Soravtansine Clinical Assessment

The report provides the clinical trials information of mirvetuximab soravtansine for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mirvetuximab soravtansine dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to mirvetuximab soravtansine and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mirvetuximab soravtansine in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of mirvetuximab soravtansine from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mirvetuximab soravtansine in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of mirvetuximab soravtansine?
• What is the clinical trial status of the study related to mirvetuximab soravtansine in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mirvetuximab soravtansine development?
• What are the key designations that have been granted to mirvetuximab soravtansine for ovarian cancer?
• What is the forecasted market scenario of mirvetuximab soravtansine for ovarian cancer?
• What are the forecasted sales of mirvetuximab soravtansine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to mirvetuximab soravtansine for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?